Q Therapeutics, Inc.: 10-K filed 2013-03-28

Name: Q Therapeutics, Inc.: 10-K filed 2013-03-28
Creator: Q Therapeutics, Inc.

What Q Therapeutics, Inc. reported in its annual report filed 2013-03-28 (fiscal FY 2012): 28 published measures, 82 facts as tagged in accession 0001193125-13-132420.

This filing

Form: 10-K (annual report)
Filed: 2013-03-28
Fiscal period: fiscal FY 2012
Accession: 0001193125-13-132420 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Q Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2012-12-31	1,305,932	USD
At 2011-12-31	2,834,751	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2012-12-31	4,990	USD
At 2011-12-31	2,540,957	USD
At 2009-12-31	-281,450	USD
At 2008-12-31	-13,214,519	USD
At 2002-03-28	0	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2012-12-31	794,207	USD
At 2011-12-31	2,741,519	USD
At 2010-12-31	422,198	USD
At 2002-03-28	0	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	-3,057,840	USD	366
2002-03-29 to 2012-12-31	-20,492,278	USD	3931
2011-01-01 to 2011-12-31	-2,599,338	USD	365
2010-01-01 to 2010-12-31	-2,599,338	USD	365
2009-01-01 to 2009-12-31	-755,731	USD	365
2002-03-29 to 2008-12-31	-13,214,519	USD	2470

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	-2,121,749	USD	366
2002-03-29 to 2012-12-31	-16,472,601	USD	3931
2011-01-01 to 2011-12-31	-1,665,370	USD	365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	2,363	USD	366
2002-03-29 to 2012-12-31	407,471	USD	3931
2011-01-01 to 2011-12-31	5,627	USD	365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	485,031	USD	366
2002-03-29 to 2012-12-31	1,373,159	USD	3931
2011-01-01 to 2011-12-31	174,573	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	176,800	USD	366
2002-03-29 to 2012-12-31	17,674,279	USD	3931
2011-01-01 to 2011-12-31	3,990,318	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2012-12-31	-20,492,278	USD
At 2011-12-31	-17,434,438	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2012-01-01 to 2012-12-31	USD	366
2002-03-29 to 2012-12-31	USD	3931
2011-01-01 to 2011-12-31	USD	365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2012-12-31	16,044	USD
At 2011-12-31	31,923	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	160,237	USD	366
2002-03-29 to 2012-12-31	431,801	USD	3931
2011-01-01 to 2011-12-31	42,378	USD	365
2010-01-01 to 2010-12-31	42,378	USD	365
2009-01-01 to 2009-12-31	42,776	USD	365
2002-03-29 to 2008-12-31	103,112	USD	2470

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	-3,062,378	USD	366
2002-03-29 to 2012-12-31	-18,718,968	USD	3931
2011-01-01 to 2011-12-31	-1,837,273	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2012-12-31	1,282,375	USD
At 2011-12-31	2,795,315	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	2,237	USD	366
2002-03-29 to 2012-12-31	2,111,414	USD	3931
2011-01-01 to 2011-12-31	763,088	USD	365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2012-12-31	1,300,942	USD
At 2011-12-31	293,794	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2012-12-31	1,203,365	USD
At 2011-12-31	77,181	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	3,547,409	USD	366
2002-03-29 to 2012-12-31	20,092,127	USD	3931
2011-01-01 to 2011-12-31	2,011,846	USD	365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	2,089,321	USD	366
2002-03-29 to 2012-12-31	10,972,892	USD	3931
2011-01-01 to 2011-12-31	444,834	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2012-12-31	24,761,832	shares
At 2011-12-31	24,582,632	shares

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2012-12-31	407,691	USD
At 2011-12-31	405,328	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2012-12-31	-391,647	USD
At 2011-12-31	-373,405	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2012-12-31	9,685	USD
At 2011-12-31	24,212	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2012-12-31	10,366	USD
At 2011-12-31	0	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	1,458,088	USD	366
2002-03-29 to 2012-12-31	9,119,235	USD	3931
2011-01-01 to 2011-12-31	1,567,012	USD	365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	2,501	USD	366
2002-03-29 to 2012-12-31	150,488	USD	3931
2011-01-01 to 2011-12-31	476	USD	365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	4,538	USD	366
2002-03-29 to 2012-12-31	-1,773,310	USD	3931
2011-01-01 to 2011-12-31	-762,065	USD	365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	190,000	USD	366
2002-03-29 to 2012-12-31	3,821,137	USD	3931
2011-01-01 to 2011-12-31	3,630,318	USD	365

Inspect the source

Entity: Q Therapeutics, Inc. / CIK 0001366541
Captured: 2026-09-22 19:44 UTC
SEC response SHA-256: 44c4e52011cdb12665e730e871f0d1a160eb40f2d3802dae8e8edfdd09adf9be

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001366541.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))